Reoperation Rate 4 Percent for Mesh-Based Prolapse Surgery

Share this content:
Reoperation Rate 4 Percent for Mesh-Based Prolapse Surgery
Reoperation Rate 4 Percent for Mesh-Based Prolapse Surgery

WEDNESDAY, June 15, 2016 (HealthDay News) -- For women undergoing mesh-based prolapse surgery, the reoperation rate is 4.0 percent at a median of 1.17 years, with reduced risk for patients of surgeons with very high volume, according to a study published in the July issue of Obstetrics and Gynecology.

Erin C. Kelly, M.D., from the University of Western Ontario in London, Canada, and colleagues conducted a retrospective, population-based cohort study involving all women who underwent mesh-based prolapse procedures between 2002 and 2013. The authors examined the proportion of women who underwent surgical revision of the mesh, with the primary exposure of surgeon volume. Data were included for 5,488 women who underwent mesh implantation by one of 368 unique surgeons; median follow-up was 5.4 years.

The researchers found that at a median of 1.17 years after implantation, 4.0 percent of women underwent mesh reoperation. Patients of very high-volume surgeons had a lower risk of reoperation for complications (3.0 versus 4.8 percent; adjusted hazard ratio, 0.59). Younger age, concomitant hysterectomy, blood transfusion, and increased medical comorbidity correlated with vaginal mesh reoperation in multivariable modeling.

"Approximately 5 percent of women who underwent mesh-based prolapse surgery required reoperation for a mesh complication within 10 years," the authors write. "The risk of reoperation was lowest for surgeons performing 14 or more procedures per year."

One author disclosed financial ties to Astellas Canada.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

MiniMed 670G hybrid closed loop system automatically monitors glucose, delivers insulin

More Evidence HPV Vaccine Protects Against Cervical Cancer

More Evidence HPV Vaccine Protects Against Cervical Cancer

Protection appears to occur even when only one or two of the recommended doses are given

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Study of millions of health records suggests an association

is free, fast, and customized just for you!

Already a member?

Sign In Now »